Published in Alzheimers Dement on July 01, 2005
A Study of Brain Aging in Vietnam War Veterans (DOD-ADNI) | NCT01687153
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Visualization of image data from cells to organisms. Nat Methods (2010) 3.66
Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage (2010) 3.58
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
Retracted Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease. Nature (2013) 3.35
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res (2009) 3.31
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One (2009) 2.85
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain (2009) 2.51
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage (2009) 2.47
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Efficient, Distributed and Interactive Neuroimaging Data Analysis Using the LONI Pipeline. Front Neuroinform (2009) 2.29
Provenance in neuroimaging. Neuroimage (2008) 2.28
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage (2009) 2.22
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol (2015) 2.21
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
Neuroimaging study designs, computational analyses and data provenance using the LONI pipeline. PLoS One (2010) 2.13
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A (2010) 2.12
The NKI-Rockland Sample: A Model for Accelerating the Pace of Discovery Science in Psychiatry. Front Neurosci (2012) 2.12
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging (2010) 2.05
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Ensemble sparse classification of Alzheimer's disease. Neuroimage (2012) 1.84
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain (2015) 1.82
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol (2011) 1.75
Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease. Neuroimage (2009) 1.71
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement (2010) 1.70
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage (2010) 1.69
Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging (2010) 1.69
Cognitive neuroscience 2.0: building a cumulative science of human brain function. Trends Cogn Sci (2010) 1.67
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage (2009) 1.63
Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2009) 1.61
Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Hum Brain Mapp (2010) 1.55
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp (2011) 1.53
Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging (2009) 1.51
Open access series of imaging studies: longitudinal MRI data in nondemented and demented older adults. J Cogn Neurosci (2010) 1.49
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Clinical applications of the functional connectome. Neuroimage (2013) 1.48
Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage (2010) 1.45
Do brain image databanks support understanding of normal ageing brain structure? A systematic review. Eur Radiol (2012) 1.44
Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic. J Am Geriatr Soc (2010) 1.42
SUMA. Neuroimage (2011) 1.40
High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord (2009) 1.33
APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol (2010) 1.30
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging (2010) 1.30
Power calculations for clinical trials in Alzheimer's disease. J Alzheimers Dis (2011) 1.30
Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol (2010) 1.29
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2006) 1.28
Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement (2012) 1.27
Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia (2007) 1.26
Multisite neuroimaging trials. Curr Opin Neurol (2009) 1.25
An automated procedure for the assessment of white matter hyperintensities by multispectral (T1, T2, PD) MRI and an evaluation of its between-centre reproducibility based on two large community databases. Neuroradiology (2007) 1.20
Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging (2010) 1.19
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
From phenotype to genotype: an association study of longitudinal phenotypic markers to Alzheimer's disease relevant SNPs. Bioinformatics (2012) 1.18
Sparse Multi-Task Regression and Feature Selection to Identify Brain Imaging Predictors for Memory Performance. Proc IEEE Int Conf Comput Vis (2011) 1.17
Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement (2012) 1.15
A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 1.14
The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia. Neuroinformatics (2013) 1.14
Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimers Dement (2010) 1.14
In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. J Neurol (2009) 1.10
Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiol Aging (2010) 1.10
Emerging imaging tools for use with traumatic brain injury research. J Neurotrauma (2011) 1.10
Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging (2010) 1.09
Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. J Rehabil Res Dev (2009) 1.08
Local mechanical properties of white matter structures in the human brain. Neuroimage (2013) 1.07
Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment. Alzheimers Dement (2010) 1.07
Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease. J Alzheimers Dis (2010) 1.07
Analysis of sampling techniques for imbalanced data: An n = 648 ADNI study. Neuroimage (2013) 1.06
Predicting language outcome and recovery after stroke: the PLORAS system. Nat Rev Neurol (2010) 1.06
Automatic analysis (aa): efficient neuroimaging workflows and parallel processing using Matlab and XML. Front Neuroinform (2015) 1.06
Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06
TRACTOGRAPHY DENSITY AND NETWORK MEASURES IN ALZHEIMER'S DISEASE. Proc IEEE Int Symp Biomed Imaging (2013) 1.05
The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. Alzheimers Dement (2008) 1.05
High-throughput neuroimaging-genetics computational infrastructure. Front Neuroinform (2014) 1.03
Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. Neuroimage (2013) 1.03
Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2010) 1.03
DTI analyses and clinical applications in Alzheimer's disease. J Alzheimers Dis (2011) 1.02
Alzheimer 100--highlights in the history of Alzheimer research. J Neural Transm (Vienna) (2006) 1.01
Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis (2012) 1.01
Trends in the prevalence of dementia in Japan. Int J Alzheimers Dis (2012) 1.01
A Federated Network for Translational Cancer Research Using Clinical Data and Biospecimens. Cancer Res (2015) 1.00
Multivariate models of inter-subject anatomical variability. Neuroimage (2010) 0.99
Neuroinformatics Database (NiDB)--a modular, portable database for the storage, analysis, and sharing of neuroimaging data. Neuroinformatics (2013) 0.98
Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med (2008) 0.98
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking. Alzheimers Dement (2012) 0.98
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci (2003) 7.26
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology (2005) 5.76
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging (1998) 5.05
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci (2003) 4.75
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb Cortex (2004) 3.87
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology (2005) 3.22
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology (2005) 3.14
Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging (2002) 3.09
Correlation between rates of brain atrophy and cognitive decline in AD. Neurology (1999) 3.07
Treatment of Alzheimer's disease. N Engl J Med (1999) 3.03
Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology (2003) 2.85
Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet (2004) 2.81
Looking backward to move forward: early detection of neurodegenerative disorders. Science (2003) 2.65
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol (2002) 2.58
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci (2005) 2.44
1H MR spectroscopy in common dementias. Neurology (2004) 2.39
MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging (2004) 2.29
Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol (2003) 2.26
Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Neurology (1996) 2.23
Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imaging (2003) 2.16
Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain (2004) 2.06
Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord (2004) 2.04
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology (2001) 1.92
Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des (2004) 1.90
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.89
Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol (2001) 1.88
Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology (2003) 1.87
In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology (1999) 1.86
Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci (2002) 1.83
Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology (1999) 1.80
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology (1997) 1.77
Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull (2003) 1.76
Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol (2000) 1.73
In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med (1999) 1.66
Radial width of the temporal horn: a sensitive measure in Alzheimer disease. AJNR Am J Neuroradiol (2002) 1.66
In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med (2004) 1.65
Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology (2004) 1.64
Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr (1998) 1.54
Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects. Neuroimage (2004) 1.53
The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res (2004) 1.53
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage (2002) 1.44
Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women. Neurology (2001) 1.43
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42
DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2005) 1.41
Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology (1996) 1.40
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol (1996) 1.39
The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. Arch Gen Psychiatry (1997) 1.38
HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med (1994) 1.38
The relationship between fMRI activation and cerebral atrophy: comparison of normal aging and alzheimer disease. Neuroimage (2000) 1.37
Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: patterns of functional MRI activation. J Int Neuropsychol Soc (1999) 1.32
Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology (1997) 1.30
Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology (2005) 1.28
Evaluating the function of hippocampal subregions with high-resolution MRI in Alzheimer's disease and aging. Microsc Res Tech (2000) 1.28
Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med (2005) 1.27
Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease. Neuroimage (1997) 1.27
Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology (2005) 1.26
No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage (2004) 1.26
Alzheimer disease therapeutics. J Neuropathol Exp Neurol (2001) 1.25
Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc (2003) 1.22
Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology (2003) 1.22
Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med (2004) 1.22
Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol (1998) 1.21
Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med (2004) 1.19
MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology (2000) 1.19
Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord (2002) 1.16
Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med (2002) 1.15
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol Res (2004) 1.14
Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet (1997) 1.13
Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology (1998) 1.13
Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci (2004) 1.12
The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiol Aging (2002) 1.11
A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord (2002) 1.10
Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology (1997) 1.10
Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology (1996) 1.10
A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord (2001) 1.05
F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal (2005) 1.04
Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol (2000) 1.02
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 17.86
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Mild cognitive impairment. Lancet (2006) 10.21
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
Longitudinal mapping of cortical thickness and brain growth in normal children. J Neurosci (2004) 7.30
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage (2007) 7.04
Dynamics of gray matter loss in Alzheimer's disease. J Neurosci (2003) 7.03
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage (2008) 6.58
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The LONI Pipeline Processing Environment. Neuroimage (2003) 5.47
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage (2004) 5.07
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci (2004) 4.14
Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage (2004) 4.13
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00